Market closedNon-fractional
Fortress Biotech/FBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Fortress Biotech
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Ticker
FBIO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Bay Harbor Islands, United States
Employees
186
Website
www.fortressbiotech.com
Fortress Biotech Metrics
BasicAdvanced
$58M
Market cap
-
P/E ratio
-$5.87
EPS
1.55
Beta
-
Dividend rate
Price and volume
Market cap
$58M
Beta
1.55
Financial strength
Current ratio
1.329
Quick ratio
1.071
Long term debt to equity
-2,007.595
Total debt to equity
-2,251.994
Interest coverage (TTM)
-8.58%
Management effectiveness
Return on assets (TTM)
-34.13%
Return on equity (TTM)
-1,739.64%
Valuation
Price to revenue (TTM)
0.327
Price to book
2.23
Price to tangible book (TTM)
14.48
Price to free cash flow (TTM)
-0.229
Growth
Revenue change (TTM)
32.48%
Earnings per share change (TTM)
-63.82%
3-year revenue growth (CAGR)
24.35%
3-year earnings per share growth (CAGR)
-11.40%
What the Analysts think about Fortress Biotech
Analyst Ratings
Majority rating from 4 analysts.
Fortress Biotech Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$13M
-34.67%
Net income
-$15M
67.39%
Profit margin
-118.46%
156.24%
Fortress Biotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.60
-$0.94
-$1.28
-$1.03
-
Expected
-$3.41
-$3.21
-$1.97
-$1.73
-$1.22
Surprise
5.49%
-70.68%
-34.92%
-40.46%
-
Fortress Biotech News
AllArticlesVideos
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
GlobeNewsWire·2 days ago
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
GlobeNewsWire·2 days ago
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fortress Biotech stock?
Fortress Biotech (FBIO) has a market cap of $58M as of July 27, 2024.
What is the P/E ratio for Fortress Biotech stock?
The price to earnings (P/E) ratio for Fortress Biotech (FBIO) stock is 0 as of July 27, 2024.
Does Fortress Biotech stock pay dividends?
No, Fortress Biotech (FBIO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Fortress Biotech dividend payment date?
Fortress Biotech (FBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Fortress Biotech?
Fortress Biotech (FBIO) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Fortress Biotech stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.